Published in Clin Cancer Res on December 30, 2014
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity (2016) 0.96
Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep (2014) 0.93
HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology (2015) 0.83
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer (2015) 0.80
A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2. Clin Cancer Res (2015) 0.80
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev (2017) 0.77
Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer. Oncoimmunology (2016) 0.76
HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep (2016) 0.76
HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res (2016) 0.75
IGPR-1 Is Required for Endothelial Cell-Cell Adhesion and Barrier Function. J Mol Biol (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity (2003) 3.18
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Functional classification of immune regulatory proteins. Structure (2013) 1.49
Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev (2009) 1.39
B7-H5 costimulates human T cells via CD28H. Nat Commun (2013) 1.19
Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC. Immunogenetics (2012) 1.12
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A (2013) 1.12
Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis. Mol Biol Cell (2012) 1.11
Host b7x promotes pulmonary metastasis of breast cancer. J Immunol (2013) 1.05
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med (2011) 1.01
Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Rep (2014) 0.89
Immune dysregulation in autism spectrum disorder. Eur J Pediatr (2013) 0.88
T cell coinhibition and immunotherapy in human breast cancer. Discov Med (2012) 0.85
Functional clustering of immunoglobulin superfamily proteins with protein-protein interaction information calibrated hidden Markov model sequence profiles. J Mol Biol (2013) 0.82
B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two cities. Oncoimmunology (2013) 0.82
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev (2017) 0.77
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin Cancer Res (2016) 0.76
HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res (2016) 0.75
Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. Mol Genet Genomic Med (2017) 0.75